Conference Coverage

Obesity may attenuate anti-TNF response in psoriatic arthritis


 

References

DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.

Pages

Recommended Reading

Severe psoriasis, kidney disease linked
Psoriasis Collection
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
Psoriasis Collection
How to beat apremilast-induced diarrhea
Psoriasis Collection
Psoriasis tied to abdominal aortic aneurysm in nationwide study
Psoriasis Collection
Effective psoriasis therapy may reduce coronary plaque burden
Psoriasis Collection
Brodalumab effective for rare, severe types of psoriasis
Psoriasis Collection
Serious infections are increasing among psoriasis inpatients
Psoriasis Collection
Full resolution of psoriasis in half of ixekizumab patients
Psoriasis Collection
TNF blocker safety may differ in RA and psoriasis patients
Psoriasis Collection
TB still a risk in psoriasis patients taking TNF blockers
Psoriasis Collection